Liver Cirrhosis – Latest Pharmaceutical and Healthcare Pipeline Guide – The PostScript

A new research paper is added in the 96-page HTF MI database, titled as ‘Liver Cirrhosis – Pipeline Review, H2 2022’ with detailed analysis, competitive landscape, forecasts and strategies. The latest analysis highlights the high-growth emerging players and leaders by market share that are currently attracting exceptional attention. The identification of hot and emerging players was complemented by the profiling of more than 50 industry players; some of the profiled players are Conatus Pharmaceuticals Inc, Galectin Therapeutics Inc, Gilead Sciences Inc, Human Stem Cells Institute, International Stem Cell Corp, Ocera Therapeutics Inc, Pharmicell Co Ltd, S-Evans Biosciences Inc, Stelic Institute & Co Inc, Stempeutics Research Pvt Ltd, VESSL Therapeutics Ltd. The market has been growing continuously over the past few years and is expected to experience some stability after Q2 2022 and may grow further in the forecast year 2021-2026

Access a sample report @

HTF’s latest Pharmaceutical and Healthcare Diseases Pipeline Guide Liver Cirrhosis – Pipeline Review, H2 2022, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape.

Cirrhosis is scarring of the liver caused by many forms of liver disease and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver, which affects the normal circulation of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, fatigue, weakness, and nausea. Treatment includes a liver transplant.

Report Highlights
The latest HTF Pharmaceutical and Healthcare Liver Cirrhosis Pipeline Guide – Pipeline Review, H2 2022, provides comprehensive information on treatments in development for cirrhosis of the liver (gastrointestinal), with analysis by stage of development, target drug, mechanism of action (MoA), route of administration (RoA) and type of molecule. The guide covers the therapeutic’s descriptive pharmacological action, its full research and development history, and the latest news and press releases.

The Cirrhosis of the Liver (Gastrointestinal) Pipeline Guide also reviews the key players involved in cirrhosis of the liver therapeutic development and features dormant and discontinued projects. The guide covers therapeutics in development by companies/universities/institutes, molecules developed by companies in phase III, phase II, phase I, preclinical and discovery are respectively 1, 6, 3, 5 and 1. Similarly, the portfolio of Universities in the Preclinical and Discovery phases includes 1 and 1 molecules respectively.

Liver Cirrhosis (Gastrointestinal) Pipeline guide helps to identify and track emerging market players and their portfolios, enhances decision-making abilities, and assists in creating effective counter-strategies to gain competitive advantage . The guide is constructed using data and information from HTF proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, Featured investor presentations and press releases from company/academic sites and industry-specific third-party sources.

Reasons to buy
– Acquire strategically important competitor information, analysis and insights to formulate effective R&D strategies.
– Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for cirrhosis of the liver (gastrointestinal).
– Classify potential new customers or partners into the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Formulate corrective measures for pipeline projects by understanding Liver Cirrhosis (Gastrointestinal) pipeline depth and focus of indication therapeutics.

Purchase single user license of this report at USD2000 @

It is essential that you keep your knowledge of the market up to date. If you have a different set of players/manufacturers by geography or need reports segmented by region or country, we can provide customization accordingly.

Contact us:
CRAIG FRANCIS (Public Relations and Marketing Manager)
[email protected]
Phone: +1 (434) 299-0043

Join us on LinkedIn | Facebook | Twitter